ExonHit Therapeutics Inc.: AclarusDx®: Launch of Observational Study in France
PARIS--(BUSINESS WIRE)--Regulatory News:
•AclarusDx® real-life observational study •First patient should be recruited in December Exonhit (Paris:ALEHT) announced today the launch of its observational study in France aimed at evaluating the performance of AclarusDx®, a blood-based test intended to aid in the diagnosis of Alzheimer’s disease (AD), in patients consulting for the first time with a specialized memory center for AD diagnostic work-up. This real-life study named DIALOG (DIagnostic ALzheimer cOGnitif) is sponsored by Exonhit and has received all regulatory approvals.
•AclarusDx® real-life observational study •First patient should be recruited in December Exonhit (Paris:ALEHT) announced today the launch of its observational study in France aimed at evaluating the performance of AclarusDx®, a blood-based test intended to aid in the diagnosis of Alzheimer’s disease (AD), in patients consulting for the first time with a specialized memory center for AD diagnostic work-up. This real-life study named DIALOG (DIagnostic ALzheimer cOGnitif) is sponsored by Exonhit and has received all regulatory approvals.